Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 27 for “"Gallium-68"”.

  1. Gallium-68 DOTATATE PET/CT in Neuroendocrine Tumors

    BACKGROUND: Ga-68 DOTATATE PET/CT has been increasingly used for diagnosis and therapy response assessment of patients with neuroendocrine tumors (NETs). Point spread function (PSF) modeling is a partial volume correction method that can be used within PET imaging reconstruction. However, little is …

    utswmed Repository record for Gallium-68 DOTATATE PET/CT in Neuroendocrine Tumors (opens in a new tab)

  2. Gallium-essential applications of Gallium-67 and Gallium-68

    … The difference between the two metals renders gallium interesting as potential therapeutic agent to disturb iron demand in cells and pathogens. The availability of radioactive gallium (68Ga and 67Ga) helps facilitate the use of gallium as an iron mimic for radionuclide imaging purposes. The …

    kings Repository record for Gallium-essential applications of Gallium-67 and Gallium-68 (opens in a new tab) Download PDF for Gallium-essential applications of Gallium-67 and Gallium-68 (opens in a new tab)

  3. New approaches to radionuclide imaging of cancer with gallium-68

    The positron emitting isotope 68Ga is gaining increasing interest in the radionuclide imaging community, due to its favourable decay properties and availability from a generator. Incorporation of 68Ga into biomolecules requires conjugation to a bifunctional chelator. The tris(hydroxypyridinone) …

    kings Repository record for New approaches to radionuclide imaging of cancer with gallium-68 (opens in a new tab) Download PDF for New approaches to radionuclide imaging of cancer with gallium-68 (opens in a new tab)

  4. A New Gallium-68 Labelled Imaging Agent for Prostate Cancer

    … for imaging PCa. The radionuclide used is gallium-68 (68Ga), which is a generator based metallic radionuclide with a half-life of 68 min.<br/><br/>A comparative study of CP256 with other gallium chelators such as NOTA, DOTA and HBED showed that CP256 gave a higher radiolabelling yield and …

    kings Repository record for A New Gallium-68 Labelled Imaging Agent for Prostate Cancer (opens in a new tab) Download PDF for A New Gallium-68 Labelled Imaging Agent for Prostate Cancer (opens in a new tab)

  5. Development and evaluation of a novel germanium-68/gallium-68 generator

    … and evaluate a novel mother/daughter Germanium-68/Gallium-68 generator for PET imaging. This type of generator has been investigated for over fifty years but many problems still exist which need to be resolved before application in a clinical setting can be achieved. Such problems include metal …

    missouri Repository record for Development and evaluation of a novel germanium-68/gallium-68 generator (opens in a new tab)

  6. Untersuchungen zum Gallium-68-DOTATOC Uptake in gesundem und pathologisch verändertem Schilddrüsengewebe

    … nachgewiesen werden. Mittels Gallium-68 (Ga-68) DOTA-Phe(1)-Tyr(3)-Octreotid (DOTATOC) Positronen-Emissions-Tomographie (PET), einem nuklearmedizinischen Untersuchungsverfahren, ist die funktionelle Darstellung der SSTR-Expression in vivo möglich. Unser Studienziel war es, den …

    qucosa-diss

  7. Design and synthesis of novel compounds as fatty acids binding protein inhibitors and as gallium-68 chelators for positron emission tomography

    … conjugated to a small molecule able to chelate gallium, for their potential applicability as PET tracers. The two compounds were then evaluated as effective 68-gallium chelating compounds and the result showed their capability in the binding of the 68Ga.

    catania Repository record for Design and synthesis of novel compounds as fatty acids binding protein inhibitors and as gallium-68 chelators for positron emission tomography (opens in a new tab)

  8. Functionalized Bispidines and Ultrasmall Silicon Nanoparticles for Cancer Imaging

    … as Copper-64 and NOTA as Copper-64 as well as Gallium-68 chelators for PET. Fluorophore, IR 800 dye was used for OI. Amine-terminated ultrasmall Silicon nanoparticles (Si NPs) of size 3-5 nm were used as a multifunctional multimodal imaging core.

    qucosa-diss

  9. Imaging and Therapeutic Radiotracers for Prostate Cancer

    … speed and selectivity of its radiolabelling with gallium radioisotopes, and its potential to be developed into one-step radiopharmaceutical kits. [68Ga]Ga-THP-PSMA was assessed as a PET imaging agent and [67Ga]Ga-THP-PSMA for molecular radiotherapy due to its Auger electron emissions. <br/>The …

    kings Repository record for Imaging and Therapeutic Radiotracers for Prostate Cancer (opens in a new tab) Download PDF for Imaging and Therapeutic Radiotracers for Prostate Cancer (opens in a new tab)

  10. In-vitro-Untersuchung zum Einfluss von Therapeutika auf die PSMA- und CXCR4-Rezeptorexpression in humanen Prostatakarzinomzelllinien

    … und schlechter Prognose assoziiert. Gallium-68-PSMA PET/CT liefert genaue Kenntnisse bezüglich Ausbreitung und Fortschreiten des Tumorgeschehens. Die vorliegende Arbeit untersucht die Zusammenhänge zwischen Expression von PSMA und CXCR4 in Verbindung mit etablierten Therapeutika und …

    wurz-thes Repository record for In-vitro-Untersuchung zum Einfluss von Therapeutika auf die PSMA- und CXCR4-Rezeptorexpression in humanen Prostatakarzinomzelllinien (opens in a new tab)

  11. Contrast Agent Development for Molecular Imaging of Cancer

    … than 5% for fluorine-18 and less than 20% for gallium-68. Despite the larger errors for gallium-68, they did not largely influence pH measurements using 68Ga-labeled PET co-agents. The power of PET/MRI was also utilized to identify lung tumor metastases and measure …

    rice Repository record for Contrast Agent Development for Molecular Imaging of Cancer (opens in a new tab)

  12. Towards synthesis of a novel chelator for zirconium-89

    … affinity for the radiometals zirconium-89 and gallium-68: The chelator was compared to DFO and subject to challenge assays to assess resistance to competitive metal ions, transchelation by EDTA, and non-specific protein binding. While it was evident that compound 8.1 was inferior to DFO as a …

    adelaide Repository record for Towards synthesis of a novel chelator for zirconium-89 (opens in a new tab)

  13. Development of PSMA-Targeted Radiopharmaceuticals for Routine Clinical Applications

    … Food and Drug Administration (FDA) approval of Gallium-68 labeled PSMA-11 (68Ga-PSMA-11), a positron emission tomography imaging agent for PSMA positive lesions in men with prostate cancer. In this study, the aim is to preclinically evaluate Copper-64 labeled PSMA-I&T (64Cu-PSMA-I&T), as a …

    tamu Repository record for Development of PSMA-Targeted Radiopharmaceuticals for Routine Clinical Applications (opens in a new tab)

  14. Development of A Multi-Purpose Automated Synthesis Module For Production of Novel Pet Radiopharmaceuticals

    … of novel PET radiopharmaceuticals, such as gallium-68-ethylenedicysteine-glucosamine (68Ga-ECG), [18F]fluoropropyl-α-methyltyrosine (18F-FPAMT), and [18F]fluoro-5-propylhydroxy tryptophan (18F-FTP). The specifications of this module are the flexibility for editing synthesis recipes, the …

    uthsc Repository record for Development of A Multi-Purpose Automated Synthesis Module For Production of Novel Pet Radiopharmaceuticals (opens in a new tab)

  15. A THERANOSTIC APPROACH TOWARDS PROGRAMMED DEATH-LIGAND 1 (PD-L1)

    … DK222 to contain a chelator suitable for gallium-68 (diagnostic) and lutetium-177 (therapy) labeling. DK223 was designed for imaging and molecular radiotherapy (MRT) of PD-L1+ tumors, which represents a promising approach in cancer immunotherapy. The diagnostic arm, [68Ga]DK223, …

    jhu Repository record for A THERANOSTIC APPROACH TOWARDS PROGRAMMED DEATH-LIGAND 1 (PD-L1) (opens in a new tab) Embargoed until 2028-05-01

  16. Einfluss systemischer Therapeutika auf die CXCR4-Expression von Myelomzellen

    Im Zuge der Bemühungen um neue, tumorspezifische Therapieansätze für die Myelomerkrankung hat sich der C-X-C-Chemokinrezeptor 4 (CXCR4) aufgrund seiner zentralen Rolle in der Tumorgenese als vielversprechender Angriffspunkt hervorgetan. Im Sinne eines theranostischen Konzepts wird der Rezeptor …

    wurz-thes Repository record for Einfluss systemischer Therapeutika auf die CXCR4-Expression von Myelomzellen (opens in a new tab)

  17. Comparison of Ga 68 PSMA-11 and F 18 Choline for detection of prostate cancer during biochemical relapse

    … current study was to assess the utility of Ga 68 PSMA-11 (a target molecule and inhibitor of the prostate-specific membrane antigen), and F 18 Choline (a molecule that increases in level along with increases in cancer cells) in identifying biochemical relapse of PCa. The U. S. Food and Drug …

    washington Repository record for Comparison of Ga 68 PSMA-11 and F 18 Choline for detection of prostate cancer during biochemical relapse (opens in a new tab)

  18. Somatostatin-Rezeptor-gerichtete PET/CT zur Diagnostik und Stratifizierung der Peptid-Rezeptor-Radionuklid-Therapie beim kleinzelligen Lungenkarzinom

    Auf Grund der schlechten Prognose des kleinzelligen Lungenkarzinoms (SCLC), auch unter moderner und leitliniengerechter Therapie, wird anhaltend nach neuen therapeutischen Angriffspunkten gesucht. Ziel der Arbeit war einerseits die prognostische Aussagekraft der Somatostatin-Rezeptor- …

    wurz-thes Repository record for Somatostatin-Rezeptor-gerichtete PET/CT zur Diagnostik und Stratifizierung der Peptid-Rezeptor-Radionuklid-Therapie beim kleinzelligen Lungenkarzinom (opens in a new tab)

  19. Development of new radiopharmaceuticals targeting the Cholecystokinin 2 receptor

    … a fini clinici, tra questi da segnalare [68Ga]PSMA-11 e [18F]PSMA-1007 che grande importanza stanno acquisendo in diagnostica PET (Positron Emission Tomography) nella stadiazione del tumore della prostata soprattutto nel rivelare la ripresa di malattia in pazienti con bassi livelli di PSA. …

    catania Repository record for Development of new radiopharmaceuticals targeting the Cholecystokinin 2 receptor (opens in a new tab)

Page 1 of 2